Effects of osteopontin downregulation on the growth of prostate cancer PC-3 cells

Molecular Medicine Reports

Volumn 4, Issue 6, 2011, Pages 1225-1231

  Zheng, Jie ^a   Hou, Zhi Bo ^a   Jiao, Nan Lin ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Malignant phenotype; Osteopontin; Prostate cancer PC 3 cells; RNA interference

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MALE; OSTEOPONTIN; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS; TRANSFECTION;

EID: 80053101541     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.549     Document Type: Article

References (26)

1. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL and Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
2. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D and Nelson C: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052, 2005. (Pubitemid 40629107)
3. Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869, 2010.
4. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE and Chung LW: Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5: 2271-2277, 1999. (Pubitemid 29399287)
5. Angelucci A, Festuccia C, D'Andrea G, Teti A and Bologna M: Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem 383: 229-234, 2002. (Pubitemid 34224046)
6. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K and Ke Y: Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118: 2255-2261, 2006.
7. Robertson BW, Bonsal L and Chellaiah MA: Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 9: 260-270, 2010.
8. Zhang Y, Forootan SS, Kamalian L, Bao ZZ, Malki MI, Foster CS and Ke Y: Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Int J Oncol 38: 1083-1091, 2011.
9. Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213, 2002. (Pubitemid 34969582)
10. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS and Khvorova A: Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330, 2004. (Pubitemid 38295766)
11. Song J, Zhang DS and Zheng J: Expression of CD44v6 gene in normal human peripheral blood. World J Gastroenterol 11: 3591-3594, 2005.
12. Zheng J, Deng YP, Lin C, Fu M, Xiao PG and Wu M: Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 82: 286-292, 1999. (Pubitemid 29293790)
13. Sinha R and Medina D: Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis 18: 1541-1547, 1997. (Pubitemid 28134777)
14. Unni E, Kittrell FS, Singh U and Sinha R: Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 6: R586-R592, 2004.
15. Zheng J and Vaheri A: Human skin fibroblasts induce anchorage-independent growth of HPV-16-DNA-immortalized cervical epithelial cells. Int J Cancer 61: 658-665, 1995.
16. Tuck AB and Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6: 419-429, 2001.
17. Behrend EI, Craig AM, Wilson SM, Denhardt DT and Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54: 832-837, 1994. (Pubitemid 24068345)
18. Muramatsu T, Shima K, Ohta K, Kizaki H, Ro Y, Kohno Y, Abiko Y and Shimono M: Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett 217: 87-95, 2005. (Pubitemid 39642869)
19. Wai PY, Mi Z, Gou H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B and Kuo PC: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26: 741-751, 2005. (Pubitemid 41214336)
20. Gong M, Lu Z, Fang G, Bi J and Xue X: A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 272: 148-159, 2008.
21. Denhardt DT, Noda M, O'Regan AW, Pavlin D and Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061, 2001. (Pubitemid 32422899)
22. Ip C, Hayes C, Budnick RM and Ganther HE: Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51: 595-600, 1991.
23. Lin YH and Yang-Yen HF: The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276: 46024-46030, 2001.
24. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM and Elgavish A: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 135: 989-995, 2005. (Pubitemid 40638296)
25. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L and Zhuang SM: Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res 67: 5141-5147, 2007. (Pubitemid 46997250)
26. Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C and Bologna M: Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 59: 157-166, 2004. (Pubitemid 38481227)